RE:Question to InsightfulGreat question. They are distinctly different technologies and a different economic model. Scibase uses electrical impedance spectroscopy (EIS) to detect a melanoma.
https://investors.scibase.se/en/invest-in-scibase
It is a tool that is used at point-of-care to help dermatologists and skin specialists make a more informed decision. The product is a one and done sale and not a recurring revenue model. It will require a well educated sales network to go to each dermatologist/clinic to demonstrate this technology and its value add to the health eco system. It can only do melanomas currently. Dermatologists will view this as a add on device to assist with melanoma assessments.
MedX's technology provides flawless images of cellular disorders such as Basal cell,Melanomas,etc. and inflamatory skin disorders such as acne, measles,tropical rashes,psoriasis and patient health information through their teledermatology platform for a dermatologists to assess. Their model is a recurring revenue model. The device is placed in a high volume traffic area like a pharmacy or a med clinic and a technichian takes the image and patients information. MedX recieves revenue from the sale of the hardware and system as well as recurring revenue everytime an patients image is transmitted across their platform.
MedX is currently valued at $23,6 million mkt cap whereas scibase is valued at ~$58 million maket cap.
I think MedX has a boader range of service nad the recurring model is much more attractive that a one and done sales model. Hope this helps.